| dc.contributor.author |
Majumder, Syamantak |
|
| dc.date.accessioned |
2021-10-02T17:47:01Z |
|
| dc.date.available |
2021-10-02T17:47:01Z |
|
| dc.date.issued |
2017-11-15 |
|
| dc.identifier.uri |
https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjIwLySvKHzAhUFiOYKHaWqCb0QFnoECAIQAQ&url=https%3A%2F%2Fjournals.physiology.org%2Fdoi%2Fpdf%2F10.1152%2Fajprenal.00445.2017&usg=AOvVaw2kMwzJwNLNsB_p_BJcDksd |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/2409 |
|
| dc.description.abstract |
Focal segmental glomerulosclerosis (FSGS) is characterized by proteinuria and renal function decline, leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD; Ref. 15). Approximately 55% of patients with idiopathic FSGS with high-grade proteinuria will proceed to ESRD at 10 yr following
diagnosis (40). The FSGS lesion can also develop as the end result of a spectrum of sources of glomerular injury, obesity, and reduced nephron mass. Despite current therapies including renin-angiotensin-aldosterone system (RAAS) inhibitors, antihypertensives, and immunosuppressants, clinical outcomes remain suboptimal. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
American Physiological Society |
en_US |
| dc.subject |
Biology |
en_US |
| dc.subject |
Dapagliflozin |
en_US |
| dc.title |
Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study |
en_US |
| dc.type |
Article |
en_US |